Nowadays, the US Drug Enforcement Administration (DEA) classifies copyright being a Schedule II drug, recognizing its superior potential for abuse but nonetheless allowing its minimal use for clinical reasons. On the other hand, existing pharmacoepidemiological tendencies recommend that copyright mi